This work aimed to characterize MYC-associated vulnerabilities to target MYC deregulated pancreatic cancer with a PRMT5 inhibitor. CRISPR models confirmed an increased sensitivity of the PRMT5i in cell lines with an upregulated MYC network. Furthermore, a sensitive PDAC subtype was characterized via the use of patient-derived cell and organoid lines. Mechanistically, PRMT5 inhibition induced DNA-damage and decreased the glycolytic activity in cells with a high MYC level. In addition, treated cells were arrested in the G2M-phase. An upregulation of the alternative splicing network was also linked to a higher sensitivity.
«
This work aimed to characterize MYC-associated vulnerabilities to target MYC deregulated pancreatic cancer with a PRMT5 inhibitor. CRISPR models confirmed an increased sensitivity of the PRMT5i in cell lines with an upregulated MYC network. Furthermore, a sensitive PDAC subtype was characterized via the use of patient-derived cell and organoid lines. Mechanistically, PRMT5 inhibition induced DNA-damage and decreased the glycolytic activity in cells with a high MYC level. In addition, treated cel...
»